Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Biogen Idec |
---|---|
Information provided by: | Biogen Idec |
ClinicalTrials.gov Identifier: | NCT00048555 |
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL], has in this patient population.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma |
Drug: IDEC-114 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma |
Estimated Enrollment: | 90 |
Study Start Date: | November 2002 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 114-21 |
Study First Received: | November 1, 2002 |
Last Updated: | September 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00048555 |
Health Authority: | United States: Food and Drug Administration |
Antibodies, Monoclonal Lymphatic Diseases Antibodies Immunoproliferative Disorders Rituximab Lymphoma, small cleaved-cell, diffuse |
Lymphoma, Follicular Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma Follicular lymphoma Immunoglobulins |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |